Leeds Institute of Cancer and Pathology

Pre-Cancer Genomics

Caroline Conway – Postdoctoral Scientist

Contact Information

Dr Caroline Conway
Section of Pre-Cancer Genomics
Leeds Institute of Cancer and Pathology
Wellcome Trust Brenner Building
St James’s University Hospital
LS9 7TF, Leeds
United Kingdom
Tel: +44 (0)113 3438417
e-mail: c.a.conway@leeds.ac.uk





I am a postdoctoral Scientist working in the Pre-cancer genomics group led by Professor Pamela Rabbitts. My current research focuses on the use of next-generation sequencing for genomic and transcriptomic analysis of pre-cancer and cancer of the upper-respiratory tract to identify molecular alterations involved in the initiation and progression of these cancers.

My role within the team has been to develop and implement methods for preparation and quality control of nucleic acids from fresh and FFPE samples prior to whole genome sequencing. I have considerable experience working with FFPE material in discovery and validation based studies and I have a key role in the planning and design of molecular assays for use on these samples in this group.

In my career to date I have focused on the identification of genetic markers in cancer that may improve the current prediction and prognostic models or available treatments for a patient with the disease. I aim to continue this focus in my future career in clinical cancer research, in particular for cancer types in which few useful molecular markers exist. I have developed a particular interest in the role of DNA damage and DNA damage response in the development and progression of cancers commonly associated with DNA damaging agents and the potential use of these as markers of the cancers propensity to metastasise.


2008 PhD, Molecular Biology, Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine.

Working with FFPE tissue I analysed commonly altered genes in primary melanomas for their association with relapse. I identified loss of gene dosage at CDKN2A as associated with relapse in melanoma. I performed gene expression profiling on a large cohort of FFPE primary melanoma samples and identified Osteopontin as an independent molecular marker of relapse in melanoma and also identified DNA repair genes as significantly associated with relapse.

2004 MRes (Distinction), University of Ulster

2003 BSc (Hons) 2.1, Biomedical Sciences with DIS, University of Ulster


Stead LF, Berri S, Wood HM, Egan P, Conway C, Daly C , Papagiannopoulos K, Rabbitts P. The transcriptional consequences of somatic amplifications, deletions and rearrangements in a human lung squamous cell carcinoma. Neoplasia 2012 Nov;14(11):1075-86.

Jewell R, Chambers P, Harland M, Laye J, Conway C, Mitra A, Elliott F, Cook MG, Boon A, Newton-Bishop J. Clinicopathologic Features of V600E and V600K Melanoma–Letter. Clin Cancer Res. 2012 Dec 15;18(24):6792

Conway C, Chalkley R, High A, Maclennan K, Berri S, Chengot P, Alsop M, Egan P, Morgan J, Taylor GR, Chester J, Sen M, Rabbitts P, Wood HM. Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumors. J Mol Diagn. 2012 Mar-Apr;14(2):104-11.

Jewell R, Mitra A, Conway C, Iremonger J, Walker C, de Kort F, Cook M, Boon A, Speirs V, Newton-Bishop J. Identification of differentially expressed genes in matched formalin-fixed paraffin-embedded primary and metastatic melanoma tumor pairs. Pigment Cell Melanoma Res. 2012 Mar;25(2):284-6.

Belvedere O, Berri S, Chalkley R, Conway C, Barbone F, Pisa F, MacLennan K, Daly C, Alsop M, Morgan J, Menis J, Tcherveniakov P, Papagiannopoulos K, Rabbitts P, Wood HM. A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma. Genomics. 2012 Jan;99(1):18-24.

Mitra A, Conway C, Walker C, Cook M, Powell B, Lobo S, Chan M, Kissin M, Layer G, Smallwood J, Ottensmeier C, Stanley P, Peach H, Chong H, Elliott F, Iles MM, Nsengimana J, Barrett JH, Bishop DT, Newton-Bishop JA. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer. 2010 Oct 12;103(8):1229-36

Jewell R*, Conway C*, Mitra A, Randerson-Moor J, Lobo S, Nsengimana J, Harland M, Marples M, Edward S, Cook M, Powell B, Boon A, de Kort F, Parker KA, Cree IA, Barrett JH, Knowles MA, Bishop DT, Newton-Bishop J. (*Contributed equally). Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res. 2010 Nov 1;16(21):5211-21

Wood HM, Belvedere O, Conway C, Daly C, Chalkley R, Bickerdike M, McKinley C, Egan P, Ross L, Hayward B, Morgan J, Davidson L, MacLennan K, Ong TK, Papagiannopoulos K, Cook I, Adams DJ, Taylor GR, Rabbitts P. Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Res. 2010 Aug;38(14):e151.

Conway C, Beswick S, Elliott F, Chang YM, Randerson-Moor J, Harland M, Affleck P, Marsden J, Sanders DS, Boon A, Knowles MA, Bishop DT, Newton-Bishop JA. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and their prognostic significance for primary melanoma. Genes Chromosomes Cancer. 2010 May; 49(5):425-38.

Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J. Gene Expression Profiling of Paraffin-Embedded Primary Melanoma using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival. Clin Cancer Res, 2009; Nov 15;15(22):6939-46


© Copyright Leeds 2018